alofantrina

Key facts

Drug.verifiedrevid

461766301

Drug.IUPAC_name

3-(Dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthryl]-1-propanol

Drug.image

Halofantrine.svg

Drug.image_class

skin-invert-image

Drug.tradename

Halfan

Drug.MedlinePlus

a603030

Drug.routes_of_administration

Oral

Drug.protein_bound

60–70%

Drug.metabolism

Hepatic (CYP3A4-mediated)

Drug.elimination_half life

6–10 days

Drug.CAS_number

69756-53-2

Drug.ATC_prefix

P01

Drug.ATC_suffix

BX01

Drug.PubChem

37393

Drug.DrugBank

DB01218

Drug.ChemSpiderID

34303

Drug.UNII

Q2OS4303HZ

Drug.ChEMBL

1107

via Wikipedia infobox

Chemical data

Formula

C26H30Cl2F3NO

Molecular weight

500.4 g/mol

IUPAC name

3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol

SMILES

CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O

InChIKey

FOHHNHSLJDZUGQ-UHFFFAOYSA-N

XLogP

8.6

Polar surface area

23.5 Ų

H-bond donors

1

H-bond acceptors

5

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

1992

Admin. routes

oral

Indications

malaria

via ChEMBL · EBI

• Halofantrine in the treatment of malaria.Lancet (London, England) · 1989
• Halofantrine.East African medical journal · 1989
• Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential.Drugs · 1992
• Clinical pharmacokinetics of halofantrine.Clinical pharmacokinetics · 1994
• Halofantrine sensitivity.Lancet (London, England) · 1993

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

499.165655

Has use

medication

via Wikidata · CC0